Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation by the proteasome. USP7 activity has been implicated in cancer progression and its overexpression is associated with tumor aggressiveness and poor prognosis in a variety of cancer types, making USP7 inhibition an attractive strategy for …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. WuXi Biology has established gastric cancer and breast cancer cell lines that …Read More >

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure.  The development of targeted therapies for overcoming drug resistance represents an unmet medical need. Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their …Read More >

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models  Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our DLL3 CAR-T cell preparation and evaluation of their anti-tumor …Read More >

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to the tumor cells themselves, as well as tied to factors within the tumor microenvironment (TME). To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has …Read More >

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the newly established paclitaxel resistant HGC27 and HCC1806 tumor models. https://onco.wuxiapptec.com Paclitaxel, known for its …Read More >

Expanded Role of PDX Models in Anticancer Drug Development Patient-derived xenograft (PDX) models are established by implanting surgically resected patient tumor tissues into immunodeficient mice and have become a pivotal tool in preclinical cancer research due to high clinical-relevance. These models faithfully preserve the original tumor’s molecular, histopathological and pharmacological characteristics, reflecting the heterogeneity and …Read More >

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells.  Although CDK4/6 inhibitors have shown promising results in the clinic, acquired resistance to these therapies is frequently observed. The successful development of next generation therapeutics necessitates a better understanding of the mechanisms underlying this …Read More >

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription factor an important drug target.  Activating point mutations in the ERα gene, especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies, and there is an urgent need to develop new strategies …Read More >